13 research outputs found

    Directed Evolution of Human Heavy Chain Variable Domain (V<sub>H</sub>) Using <i>In Vivo</i> Protein Fitness Filter

    No full text
    <div><p>Human immunoglobulin heavy chain variable domains (V<sub>H</sub>) are promising scaffolds for antigen binding. However, V<sub>H</sub> is an unstable and aggregation-prone protein, hindering its use for therapeutic purposes. To evolve the V<sub>H</sub> domain, we performed <i>in vivo</i> protein solubility selection that linked antibiotic resistance to the protein folding quality control mechanism of the twin-arginine translocation pathway of <i>E. coli</i>. After screening a human germ-line V<sub>H</sub> library, 95% of the V<sub>H</sub> proteins obtained were identified as V<sub>H</sub>3 family members; one V<sub>H</sub> protein, MG2x1, stood out among separate clones expressing individual V<sub>H</sub> variants. With further screening of combinatorial framework mutation library of MG2x1, we found a consistent bias toward substitution with tryptophan at the position of 50 and 58 in V<sub>H</sub>. Comparison of the crystal structures of the V<sub>H</sub> variants revealed that those substitutions with bulky side chain amino acids filled the cavity in the V<sub>H</sub> interface between heavy and light chains of the Fab arrangement along with the increased number of hydrogen bonds, decreased solvation energy, and increased negative charge. Accordingly, the engineered V<sub>H</sub> acquires an increased level of thermodynamic stability, reversible folding, and soluble expression. The library built with the V<sub>H</sub> variant as a scaffold was qualified as most of V<sub>H</sub> clones selected randomly were expressed as soluble form in <i>E. coli</i> regardless length of the combinatorial CDR. Furthermore, a non-aggregation feature of the selected V<sub>H</sub> conferred a free of humoral response in mice, even when administered together with adjuvant. As a result, this selection provides an alternative directed evolution pathway for unstable proteins, which are distinct from conventional methods based on the phage display.</p></div

    Far-UV CD spectra for the detection of reversible folding.

    No full text
    <p>(A) MG2x1. (B) MG8-6. (C) MG8-14. (D) Modified MG8-14 [L50W]. Black lines indicate profiles for V<sub>H</sub> in native state at 25°C; red lines indicate the profile for V<sub>H</sub> denatured at 85°C; and green lines indicate profiles for V<sub>H</sub> renatured at 25°C.</p

    Thermodynamic stability.

    No full text
    <p>(A) Representative V<sub>H</sub> domains selected from the germ-line library. (B) Representative V<sub>H</sub> domains selected from the MG2x1 frame-mutation library. The black bold line indicates the profile of the parental V<sub>H</sub>, MG2x1, prior to mutation. Folding fraction was converted from the temperature-scouting CD profile at a fixed wavelength (230 nm).</p

    Soluble expression level of screened V<sub>H</sub> domains.

    No full text
    <p>SDS-PAGE of soluble (A) and insoluble (B) fractions of <i>E. coli</i> expressing each V<sub>H</sub> domains selected from the frame-mutation library of MG2x1 were loaded as follows: 1, V<sub>HH</sub> (camel single-domain antibody); 2, HEL4; 3, MG2x1; 4, MG8-14; 5, MG2-47; 6, MG2-55; 7, MG2-57; 8, MG2-59; 9, MG4-2; 10, MG4-5; 11, MG4-6; 12, MG4-7; 13, MG4-12; 14, MG4-13; 15, MG4-17; 16, MG4-20; 17, MG4-28; 18, MG4-32; 19, MG4-33; 20, MG8-4; 21, MG8-5; 22, MG8-6; 23, MG8-8; 24, MG8-11; 25, MG8-12; 26, MG8-13. Lanes labeled ‘MW’ contained protein size markers (10 and 15 kD). U indicates fractions from a culture with no isopropylβD-1-thiogalactopyranoside.</p

    The recovery yields of selected V<sub>H</sub> after thermal stress. Data are means and standard deviation for three independent treatment of heat denaturation within the same sample.

    No full text
    a<p>Absorbance at 280 nm at 25°C.</p>b<p>Absorbance at 280 nm after heating (85°C) followed by cooling (25°C). Aggregates after heating were removed by centrifugation.</p>c<p>The recovery yield was defined as the fraction of soluble V<sub>H</sub> remaining after heating at the denaturation temperature (85°C).</p

    Frequency of mutations of the randomly chosen V<sub>H</sub> domains after screening of the combinatorial frame-mutation library of MG2x1 via TAPE.

    No full text
    a<p>Possible substitution of amino acids into the frame-mutation library (%) according to the given codon degeneracy of primers used for mutagenesis of MG2x1 as shown in the <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0098178#pone.0098178.s002" target="_blank">Table S1</a>.</p

    Humoral immune response of BALB/c mice.

    No full text
    <p>Six mice (per group) were received multiple intravenous injections of PBS (P), MG2x1 (A), MG2x1 plus CFA (A), MG8-14 (B), MG8-14 plus CFA (B), V<sub>HH</sub> (C), or V<sub>HH</sub> plus CFA (C) at week 3 (w3), week 6 (w6), and week 9 (w9). Six mice (per group) were received multiple injections of 1 µg MG8-14 intramuscularly (im, D), 1 µg MG8-14 subcutaneously (sc, D), 10 µg MG8-14 intramuscularly (im, D), 10 µg MG8-14 subcutaneously (sc, D), 1 µg V<sub>HH</sub> intramuscularly (im, E), 1 µg V<sub>HH</sub> subcutaneously (sc, E), 10 µg V<sub>HH</sub> intramuscularly (im, E), or 10 µg V<sub>HH</sub> subcutaneously (sc, E) at week 2 (w2), week 6 (w6), and week 10 (w10).</p

    Structures of MG2x1, MG8-4, and MG8-14.

    No full text
    <p>(A) Structure of MG2x1 with CDRH1 (yellow), CDRH2 (red), and CDRH3 (blue). Mutation sites for the MG2x1 mutation library are indicated as sticks (magenta). (B) Antibody light chain, in surface rendering (cyan), is shown to highlight the relative locations of CDR H1–H3 and the mutation sites in MG2x1 (magenta). The circle indicates the cavity area. (C) Superposition of three V<sub>H</sub> domains (MG2x1, MG8-4, and MG8-14), showing the variation in the loop in the CDRH3 region (blue).</p

    SDS-PAGE of soluble and insoluble fractions of <i>E.x coli</i>.

    No full text
    <p>(A) Previously characterized V<sub>H</sub> domains (V<sub>H</sub>2, V<sub>H</sub>3, V<sub>H</sub>6, DP47d, and HEL4). (B) V<sub>H</sub> domains chosen randomly from the human V<sub>H</sub> germ-line library (RD1–3) or selected from the human germ-line library using TAPE (MG4x4-44, MG4x4-25, MG10-10, and MG2x1). Cultures expressing each V<sub>H</sub> domain were harvested after induction at 25°C for 3.5 h, and soluble (S) and insoluble (I) fractions were prepared. Lane ‘MW’ contains a protein size marker; the size of each marker is indicated (in kD) to the left of each panel. In both panels, the mobilities of V<sub>H</sub> domains correspond to the 15-kD protein size marker. Different parts from separating gels are grouped to align expression patterns for soluble and insoluble fraction of each V<sub>H</sub> domain.</p
    corecore